Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma

Blood Drawing for Study of Peripheral Blood T-lymphocytes and Other Parameters in Patients With Metastatic Melanoma and Renal Cell Cancer With Spontaneous Regression

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03728842

Enrollment

Registered

2018-11-02

Start date

2004-01-04

Completion date

2027-03-01

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma; Renal Cell Carcinoma

Keywords

metastatic disease, spontaneous regression

Brief summary

The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may influence these occurrences.

Detailed description

Spontaneous regression in patients with metastatic cancer is an incredibly rare event. It has been described after infection in cancer patients and also rarely in patients with renal cell cancer (usually after resection of the renal primary) and, less commonly, in patients with metastatic melanoma. Primary Objective To collect peripheral blood from patients with metastatic melanoma and renal cell cancer and spontaneous regression for studies of immune response and other studies. Secondary Objective To collect clinical data from subjects registered to this study. Clinical data collection will include demographics and cancer characteristics, history and treatment.

Interventions

OTHERBlood collection for laboratory studies

Peripheral whole blood will be collected

OTHERData collection from medical record

Clinical data such as demographics and cancer characteristics, history and treatment will be collected

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. ≥ 18 years old at the time of informed consent 2. Ability to provide written informed consent and HIPAA authorization 3. Patients must have metastatic melanoma or renal cell cancer with spontaneous regression. 4. Willingness to undergo phlebotomy for research blood samples

Exclusion criteria

1. Concurrent disease or condition that would make the patient inappropriate for study participation or any serious medical or psychiatric disorder that would interfere with the subject's safety 2. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent

Design outcomes

Primary

Measure	Time frame	Description
Number of blood samples collected	1 year	samples collected from metastatic melanoma and renal cell cancer patients

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026